Giving colon cancer patients chemotherapy before surgery cuts their risk of the disease coming back, according to a trial we funded.
As our 20th anniversary year draws to a close, we’re celebrating some of the pioneering women who have contributed to impactful cancer research and paved the way for even more.
The Taylor Family Foundation has donated £2.1m to support the Cancer Research UK PROTIS clinical trial, a study that will…
Cancer Research UK, in partnership with tech company Stitch, are going live with an app for patients to use whilst participating in a clinical trial.
In an unusual turn of events, the results of a clinical trial for mitoxantrone turned out to be so effective that the randomisation of the trial was halted early.
The current consensus is that, right now, there isn’t a large enough body of evidence to prove that cannabis (or any of its active compounds or derivatives) can reliably treat any form of cancer but the medical use of cannabis to treat cancer-related chronic pain is approved in the UK.
Sacituzumab govitecan (Trodelvy) is not being recommended by NICE for use in England as a treatment for some people with triple-negative breast cancer.
A study by Oxford University has found that aromatase inhibitors are better than tamoxifen at reducing the risk of breast cancer recurrence in both younger and older women.
To mark 20 years since the merger of the Cancer Research Campaign and the Imperial Cancer Research Fund, we’ve delved into the research of the charities’ that led to many of the drugs in use today.
Professor Eithne Costello on the challenges of ambitious trials, the evolution of early detection as a field in its own right and why a guiding framework is all important.